Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry

Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Jignesh M ParekhPranav S Shrivastav

Abstract

A sensitive, selective and high throughput liquid chromatography tandem mass spectrometry (LC-ESI-MS/MS) method has been developed for the determination of teriflunomide, an active metabolite of leflunomide in human plasma. Plasma samples were prepared by liquid-liquid extraction of teriflunomide and valsartan as internal standard (IS) in ethyl acetate from 200microL human plasma. The chromatographic separation was achieved on an Inertsil ODS-3 C18 (50mmx4.6mm, 3microm) analytical column using isocratic mobile phase, consisting of 20mM ammonium acetate-methanol (25:75, v/v), at a flow-rate of 0.8mL/min. The precursor-->product ion transition for teriflunomide (m/z 269.0-->82.0) and IS (m/z 434.1-->350.3) were monitored on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) and negative ion mode. The method was validated over a wide dynamic concentration range of 10.1-4001ng/mL. Matrix effect was assessed by post-column infusion experiment and the mean process efficiency were 91.7% and 88.2% for teriflunomide and IS respectively. The method was rugged and rapid with a total run time of 2.0min and is applied to a bioequivalence study of 20mg leflunomide (test and reference) tablet formulatio...Continue Reading

Citations

May 7, 2011·Bioanalysis·Manish Yadav, Pranav S Shrivastav
Feb 26, 2011·Journal of Pharmaceutical and Biomedical Analysis·Halima RakhilaMichael Wiese
Dec 20, 2014·Therapeutic Drug Monitoring·Geoffrey S RuleKamisha L Johnson-Davis
Apr 10, 2020·Leukemia & Lymphoma·Michael RosenzweigSteven T Rosen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.